See the DrugPatentWatch profile for ruxolitinib

Ruxolitinib, a Janus kinase (JAK) 1 and 2 inhibitor, is used to treat certain types of myelofibrosis and polycythemia vera, two rare blood disorders. According to the prescribing information for Jakafi, the brand name of ruxolitinib produced by Incyte Corporation, the following excipients are included in the formulation:

1. Hypromellose: This is a cellulose derivative commonly used in oral medications as a binder or thickening agent.
2. Croscarmellose sodium: Another commonly used excipient, croscarmellose sodium acts as a disintegrant, helping the tablet to break down and release the active ingredient in the body.
3. Magnesium stearate: This compound is often used as a lubricant in pharmaceutical manufacturing to reduce friction during the compression of tablets.
4. Film coating: The Jakafi tablet is coated with a mixture of hypromellose, titanium dioxide, and polyethylene glycol. This coating helps to improve the drug's stability and aesthetics, as well as making it easier to swallow.

It is important to note that the excipients used in a drug formulation can vary between manufacturers. While Incyte Corporation produces Jakafi, Apotex is another company that manufactures a generic version of ruxolitinib. According to DrugPatentWatch.com, the Apotex formulation of ruxolitinib appears to contain the same excipients as Jakafi, based on the available information. However, it is always advisable to consult the prescribing information or contact the manufacturer for the most up-to-date and accurate information on drug formulations.

Sources:

1. Jakafi (ruxolitinib) tablets, for oral use [prescribing information]. Wilmington, DE: Incyte Corporation; 2021. <https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/202353s025lbl.pdf>
2. DrugPatentWatch.com. Apotex ruxolitinib. <https://www.drugpatentwatch.com/drugs/ruxolitinib/manufacturers/apotex>